NCT05798897 - Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2023

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions

Non-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, RelapsedNon Hodgkin LymphomaHodgkin LymphomaHodgkin Lymphoma, AdultHodgkin's Lymphoma, Relapsed, Adult

Interventions

DRUG

MT-601

Multi-antigen specific CD4+ andCD8+ T cells

Trial Locations (7)

10065

RECRUITING

Cornell, New York

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

66160

RECRUITING

University of Kansas Medical Center, Kansas City

78704

RECRUITING

Sarah Cannon Research Institute at St. David's South Austin, Austin

80045

RECRUITING

University of Colorado, Aurora

80218

RECRUITING

Colorado Blood Cancer Institute (Sarah Cannon), Denver

91010

RECRUITING

City of Hope, Duarte